

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FREE TRANSMITTAL
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$)**130.00****Complete if Known**

Application Number	10/677,967
Filing Date	October 2, 2003
First Named Inventor	Anke Esperester et al
Examiner Name	To be assigned
Art Unit	1614
Attorney Docket No.	1/1556

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit Account Number
Deposit Account Name

02-2955

02-2955

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	18.00	<input type="text"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X	86.00	<input type="text"/>
Multiple Dependent					290.00	<input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	130.00
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**130.00****SUBMITTED BY**

(Complete if applicable)

Name (Print/Type)	Susan K. Pocchiari	Registration No. (Attorney/Agent)	45,016	Telephone	203-798-5648
Signature	<i>Susan K. Pocchiari</i>	Date	07/07/2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Anke Esperester et al)Art Unit: 1614
Serial No. : 10/677,967)Examiner: To be assigned
Confirmation No. : 9274)Docket No.: 1/1556
Filed : October 2, 2003
For : Ambroxol for the treatment of inflammation in the pharynx

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST TO CORRECT INVENTORSHIP
PURSUANT TO 37 C.F.R. § 1.48(a)(1)

Sir:

Applicants respectfully request change of inventorship for the above-identified application by adding inventor Liane Paul. The error in not naming of the inventor occurred without any deceptive intention on the part of Liane Paul. Submitted herewith is: a statement from Liane Paul that the error occurred without deceptive intention on her part; a Declaration by each actual inventor; the processing fee as set forth in 37 C.F.R. §1.17(i); and written consent of the existing assignee, Boehringer Ingelheim Pharmaceuticals, Inc.

Respectfully submitted,

[Handwritten signature of Susan K. Pocchiari]

Susan K. Pocchiari
Attorney for Applicant(s)
Reg. No. 45,016

Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-5648

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


on July 7, 2004

[Handwritten signature of Susan K. Pocchiari]

By: Susan K. Pocchiari
Reg. No. 45,016

07/13/2004 FFANAIA2 00000080 022955 10677967

01 FC:1460 130.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Anke Esperester et al) Art Unit: 1614
Serial No. : 10/677,967) Examiner: To be assigned
Confirmation No. : 9274) Docket No.: 1/1556
Filed : October 2, 2003
For : Ambroxol for the treatment of inflammation in the pharynx

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 11, 2004

CONSENT OF ASSIGNEE
PURSUANT TO 37 C.F.R. § 1.489(a)(4)

Sir:


The assignee, Boehringer Ingelheim Pharma GmbH & Co. KG., of the above-identified application hereby gives consent to the requested inventorship correction adding inventor Liane Paul submitted herewith. I have the authority to act on behalf of the assignee.

Respectfully submitted,

Boehringer Ingelheim
Pharma GmbH & Co. KG
ppa.

Dr. H. HAMMANN

M. HOSS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Anke Esperester et al) Art Unit: 1614
Serial No. : 10/677,967) Examiner: To be assigned
Confirmation No. : 9274) Docket No.: 1/1556
Filed : October 2, 2003
For : Ambroxol for the treatment of inflammation in the pharynx

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 11, 2004

STATEMENT OF LIANE PAUL
PURSUANT TO 37 C.F.R. § 1.489(a)(2)

Sir:

The inventorship error in the above-identified application occurred
without deceptive intention on my part.

Respectfully submitted,

Liane Paul